Diabetic kidney disease (DKD) is a common complication of diabetes, affecting ∼ 40% of patients with type 2 diabetes (T2D) [1]. DKD is characterized by increased urinary albumin excretion and/or impaired glomerular filtration rate (GFR) [2]. DKD is a multifactorial disease, and obesity, systemic and glomerular hypertension, dyslipidemia, and smoking are well-known contributing factors on top of hyperglycemia. Current therapies to prevent or slow the progression of DKD are based on reducing these kidney risk factors, such as blood glucose and blood pressure control, the latter by blockers of the renin angiotensin aldosterone system (RAAS) [3].
